Opko Health (Israel) Management Performance Evaluation

OPK -- Israel Stock  

ILS 860.50  23.00  2.75%

Analysis of Opko Health manpower and management performance can provide insight into Opko Health stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with Opko Health future performance. Opko Health employes about 5690 people. The company is managed by 20 executives with total tenure of roughly 140 years, averanging almost 7.0 years of service per executive having 1.0 employee per reported executive. Additionally take a look at Your Equity Center.
  Philip Frost  Chairman
Chairman of the Board, CEO
  Phillip Frost  Chairman
Chairman of the Board, CEO
  Jon Cohen  Chairman
Executive Chairman of BioReference Laboratories

Opko Health Management Effectiveness

The company has return on total asset (ROA) of (4.0) % which means that it has lost $4.0 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (8.42) % meaning that it generated substantial loss on money invested by shareholders.

Opko Health Workforce Comparison

Opko Health is considered to be number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers - Specialty & Generic industry is now estimated at about 11,380. Opko Health totals roughly 5,690 in number of employees claiming about 50% of equities under Drug Manufacturers - Specialty & Generic industry.

Opko Health Profit Margins

The company has Profit Margin (PM) of (15.45) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (16.29) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.16.

Opko Health Stakeholders

Philip Frost Chairman of the Board, CEO
Phillip Frost Chairman of the Board, CEO
Jon Cohen Executive Chairman of BioReference Laboratories
Jane Hsiao Vice Chairman of the Board, Chief Technical Officer
Steven Rubin Executive Vice President - Administration, Director
Akhtar Ashfaq Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division
Geoff Monk President of BioReference
Adam Logal CFO, Chief Accounting Officer, Sr. VP and Treasurer
Robert Fishel Independent Director
Robert Baron Independent Director
Alice Yu Independent Director
Richard Lerner Independent Director
Dmitry Kolosov Independent Director
Richard Pfenniger Independent Director
Thomas Beier Director
John Paganelli Independent Director
Richard Krasno Independent Director
Anne Fields IR Contact Officer
Thomas Nusbickel Chief Commercial Officer of the Company's Renal Division
Miriam Miller IR Contact Officer

Opko Health Manpower Efficiency

Return on Opko Health Manpower

Revenue Per Employee174 K
Revenue Per Executive49.5 M
Net Loss Per Employee26.9 K
Net Loss Per Executive7.7 M
Additionally take a look at Your Equity Center. Please also try Financial Widgets module to easily integrated macroaxis content with over 30 different plug-and-play financial widgets.
Search macroaxis.com